Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF MAY 24, 2007 FBO #2005
SOLICITATION NOTICE

A -- Pilot Project to Estimate the Incidence of Hepatitis C Virus (HCV) Infection Among Young Injection Drug Users (IDUs) Using serial Cross-Sectional Seroprevalence Surveys

Notice Date
5/22/2007
 
Notice Type
Solicitation Notice
 
NAICS
541710 — Research and Development in the Physical, Engineering, and Life Sciences
 
Contracting Office
Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146, UNITED STATES
 
ZIP Code
00000
 
Solicitation Number
2007-N-09566
 
Response Due
6/6/2007
 
Description
Currently the Centers for Disease Control and Prevention (CDC) monitors the national incidence of acute hepatitis C through passive surveillance of acute, symptomatic cases of laboratory confirmed hepatitis C. (see http://www.cdc.gov/ncidod/diseases/hepatitis/resource/surveillance.htm#DisSpecAcuteC). This case definition requires that case-patients have laboratory markers of hepatitis C virus (HCV) infection in addition to evidence of an acute illness with a discrete onset of symptoms or jaundice, and elevated liver enzymes. However, only a minority of people with acute infection have symptoms at all (<25%) and although the case definition is highly specific, it only captures a small fraction of acutely infected people, i.e., those who have symptoms and receive medical attention and appropriate laboratory testing during the acute phase of the disease. Injection drug users (IDUs), who are the primary risk group for acute hepatitis C (70% of identified acute cases), have additional barriers to health care access and/or utilization resulting in the potential for a further underestimation of overall incidence. Thus, it is necessary to consider strategies other than passive surveillance for incidence monitoring. CDC has a requirement to contract services for a pilot project to estimate the incidence of hepatitis C Virus (HCV) infection among young injection drug users (IDUs) using serial cross-sectional Seroprevalence Surveys (SCSSs). The solicitation will be for multi-award contracts to develop and test different methods to recruit a sample of young IDUs that is representative of the population of young IDUs at risk for HCV infection in a defined geographic area. These sampling methods will be compared and contrasted to identify a methodology to be used in ongoing SCSSs among young IDUs. In addition, instruments for collecting behavioral/risk factor data from IDUs will be developed and pilot tested. This is a full and open competition. The NAICS code for this procurement is 541710. A Cost-Plus-Fixed-Fee contract in accordance with FAR 15 is contemplated. There will be two phases for this contract; Phase I will be 1 to 8 months and Phase 2 will be 9 to 24 months, total period of performance is 24 months. CDC will consider all responsible sources responding to this Request for Proposal (RFP). The RFP number 2007-N-09566 will be available on or about June 8, 2007. The due date for receipt of proposals will be 45 days after posting of the RFP. All questions/concerns pertaining to the RFP shall be submitted via email chj5@cdc.gov. The complete solicitation package will be available and posted at fedbizopps website for downloading. Telephone requests and facsimile transmissions will be not be honored.
 
Record
SN01300113-W 20070524/070522220336 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2020, Loren Data Corp.